Karin Levie

Summary

Country: Belgium

Publications

  1. ncbi An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults
    Karin Levie
    Ecole de Santé Publique, Universite Catholique de Louvain, Brussels
    J Infect Dis 198:642-9. 2008
  2. ncbi Immunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents
    Dominique Boutriau
    GlaxoSmithKline Biologicals, Rue de l Institut 89, 1330 Rixensart, Belgium
    Clin Vaccine Immunol 14:65-73. 2007
  3. ncbi Immunogenicity, reactogenicity and safety of two-dose versus three-dose (standard care) hepatitis B immunisation of healthy adolescents aged 11-15 years: a randomised controlled trial
    Leon Heron
    National Center for Immunisation Research and Surveillance of Vaccine Preventable Diseases, Childrens Hospital, Westmead, Australia
    Vaccine 25:2817-22. 2007

Collaborators

  • Geert Leroux-Roels
  • Corinne Vandermeulen
  • Leon Heron
  • Dominique Boutriau
  • Jamie Findlow
  • Francisco Dominguez
  • Bernard Hoet
  • Joan Puig-Barbera
  • Anne Diane Kervyn
  • Michel Stoffel
  • Pierre Van Damme
  • Jose Maria Baldo
  • Angels Jubert
  • Anne-Diane Kervyn
  • Jan Poolman
  • Victoria Planelles
  • Angel Gil
  • Franklin Sotolongo
  • Anna Moiseieva
  • Javier Diez Domingo
  • Marie Van der Wielen
  • Julia Colomer
  • Vincent Weynants
  • Olga Selnikova
  • Ramón Barbera
  • Ray Borrow

Detail Information

Publications3

  1. ncbi An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults
    Karin Levie
    Ecole de Santé Publique, Universite Catholique de Louvain, Brussels
    J Infect Dis 198:642-9. 2008
    ..To protect a naive global population against pandemic influenza, pandemic vaccines should be effective at low antigen doses, because of limited manufacturing capacity...
  2. ncbi Immunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents
    Dominique Boutriau
    GlaxoSmithKline Biologicals, Rue de l Institut 89, 1330 Rixensart, Belgium
    Clin Vaccine Immunol 14:65-73. 2007
    ....
  3. ncbi Immunogenicity, reactogenicity and safety of two-dose versus three-dose (standard care) hepatitis B immunisation of healthy adolescents aged 11-15 years: a randomised controlled trial
    Leon Heron
    National Center for Immunisation Research and Surveillance of Vaccine Preventable Diseases, Childrens Hospital, Westmead, Australia
    Vaccine 25:2817-22. 2007
    ..Both regimens were shown to be safe and well tolerated. Two doses of Engerix-B (20 microg HBsAg) could be considered as an alternative to standard three-dose Engerix-B (10 microg HBsAg) immunisation for adolescents aged 11-15 years...